晚期非小细胞肺癌患者的血浆D-二聚体、降钙素原水平与其无进展生存期的相关性分析  

Correlation analysis of plasma D-dimer,procalcitonin levels and progression-free survival in patients with advanced non-small cell lung cancer

作　　者：陈肖 CHEN Xiao(Xuzhou Tongshan District Hospital of Traditional Chinese Medicine,Xuzhou 221000,China)

机构地区：[1]徐州市铜山区中医院,221000

出　　处：《中国实用医药》2023年第24期51-54,共4页China Practical Medicine

摘　　要：目的分析晚期非小细胞肺癌(NSCLC)患者的血浆D-二聚体和降钙素原(PCT)水平与其无进展生存期(PFS)的相关性。方法选取50例晚期非小细胞肺癌患者作为实验组,均采用培美曲塞或紫杉醇类联合铂类化疗,根据化疗结果分为有效组(29例)和无效组(21例);另选取28例非肿瘤患者作为对照组。比较实验组和对照组化疗前血浆D-二聚体、PCT水平,有效组和无效组化疗前血浆D-二聚体、PCT水平,有效组化疗前后血浆D-二聚体、PCT水平,无效组化疗前后血浆D-二聚体、PCT水平;分析晚期非小细胞肺癌患者血浆D-二聚体和PCT与PFS的相关性。结果实验组化疗前的血浆D-二聚体(1494.66±97.39)μg/L及PCT(0.4138±0.0503)ng/ml均高于对照组的(252.00±23.96)μg/L、(0.0826±0.0160)ng/ml,差异有统计学意义(P<0.05)。化疗前,有效组患者的D-二聚体(1317.00±119.50)μg/L和PCT(0.3248±0.0424)ng/ml均低于无效组的(1740.00±150.10)μg/L、(0.5367±0.0999)ng/ml,差异有统计学意义(P<0.05)。有效组患者化疗后的D-二聚体(652.00±58.91)μg/L和PCT(0.1380±0.0368)ng/ml均低于化疗前的(1317.00±119.50)μg/L、(0.3248±0.0424)ng/ml,差异有统计学意义(P<0.05)。无效组患者化疗后的D-二聚体(2686.00±304.40)μg/L明显高于化疗前的(1740.00±150.12)μg/L,差异有统计学意义(P<0.05);无效组患者化疗后的PCT水平高于化疗前,但差异无统计学意义(P>0.05)。50例晚期非小细胞肺癌患者均随访12~36个月,随访率为100%,PFS为8.8个月,患者的血浆D-二聚体和PCT与PFS呈负相关(r=-0.835、-0.745,P<0.05)。结论血浆中D-二聚体和PCT水平的变化可用于判断晚期非小细胞肺癌患者的化疗疗效及预后。Objective To analyze the correlation of plasma D-dimer,procalcitonin(PCT)levels and progression-free survival(PFS)in patients with advanced non-small cell lung cancer(NSCLC).Methods 50 patients with advanced non-small cell lung cancer were selected as the experimental group,and received pemetrexed or paclitaxel combined with platinum chemotherapy.They were divided into effective group(29 cases)and ineffective group(21 cases)according to chemotherapy results.Another 28 non-tumor patients were selected as control group.Comparison was made on plasma D-dimer and PCT before chemotherapy between the experimental group and the control group,between the effective group and the ineffective group,as well as plasma D-dimer and PCT before and after chemotherapy in the effective group and the ineffective group.The correlation of plasma D-dimer and PCT with PFS in patients with advanced non-small cell lung cancer was analyzed.Results Plasma D-dimer of(1494.66±97.39)μg/L and PCT of(0.4138±0.0503)ng/ml in the experimental group before chemotherapy were higher than those of(252.00±23.96)μg/L and(0.0826±0.0160)ng/ml in the control group.The differences were statistically significant(P<0.05).Before chemotherapy,D-dimer of(1317.00±119.50)μg/L and PCT of(0.3248±0.0424)ng/ml in the effective group were lower than those of(1740.00±150.10)μg/L and(0.5367±0.0999)ng/ml in the ineffective group.The differences were statistically significant(P<0.05).D-dimer of(652.00±58.91)μg/L and PCT of(0.1380±0.0368)ng/ml after chemotherapy in the effective group after chemotherapy were lower than those of(1317.00±119.50)μg/L and(0.3248±0.0424)ng/ml before chemotherapy.The differences were statistically significant(P<0.05).D-dimer of(2686.00±304.40)μg/L after chemotherapy in the ineffective group was significantly higher than that of(1740.00±150.12)μg/L before chemotherapy,and the difference was statistically significant(P<0.05).PCT level in the ineffective group after chemotherapy was higher than that before chemotherapy,but the di

关 键 词：D-二聚体 降钙素原 晚期非小细胞肺癌 化疗 无进展生存期 

分 类 号：R734.2[医药卫生—肿瘤]